Rapport Research Development from 2010 to 2026
| RAPP Stock | 27.09 1.54 6.03% |
Research Development | First Reported 2010-12-31 | Previous Quarter 70.1 M | Current Value 36 M | Quarterly Volatility 19.4 M |
Check Rapport Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rapport Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 0.0 or Selling General Administrative of 26.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 13.16. Rapport financial statements analysis is a perfect complement when working with Rapport Therapeutics Valuation or Volatility modules.
Rapport | Research Development | Build AI portfolio with Rapport Stock |
Evaluating Rapport Therapeutics's Research Development across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Rapport Therapeutics Common's fundamental strength.
Latest Rapport Therapeutics' Research Development Growth Pattern
Below is the plot of the Research Development of Rapport Therapeutics Common over the last few years. It is Rapport Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rapport Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Research Development | 10 Years Trend |
|
Research Development |
| Timeline |
Rapport Research Development Regression Statistics
| Arithmetic Mean | 18,438,562 | |
| Geometric Mean | 13,308,375 | |
| Coefficient Of Variation | 105.03 | |
| Mean Deviation | 14,259,565 | |
| Median | 9,115,000 | |
| Standard Deviation | 19,365,671 | |
| Sample Variance | 375T | |
| Range | 61M | |
| R-Value | 0.67 | |
| Mean Square Error | 221T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | 2,565,569 | |
| Total Sum of Squares | 6000.5T |
Rapport Research Development History
About Rapport Therapeutics Financial Statements
Rapport Therapeutics shareholders use historical fundamental indicators, such as Research Development, to determine how well the company is positioned to perform in the future. Although Rapport Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Rapport Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Rapport Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Research Development | 70.1 M | 36 M |
Pair Trading with Rapport Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
The ability to find closely correlated positions to Rapport Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics Common to buy it.
The correlation of Rapport Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics' price analysis, check to measure Rapport Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics is operating at the current time. Most of Rapport Therapeutics' value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics' price. Additionally, you may evaluate how the addition of Rapport Therapeutics to your portfolios can decrease your overall portfolio volatility.